“Deborah agreed to take part in a trial as she was keen to help other cancer patients in the future. "If taking part in a trial means others might be helped then I’m very happy with that."
A study looking at a type of PET-CT scan for women with breast cancer (FRONTIER)
This study was done to find out whether fluciclovine PET-CT scans can show up areas of breast cancer. It was for women who were due to have treatment for breast cancer at the Churchill hospital in Oxford.
The study was open for people to join between 2017 and 2018. The team published the results in 2022.
More about this trial
A PET-CT scan combines a PET scan and a CT scan to give detailed information about a person’s cancer. It can help doctors decide the best treatment to give, and show how well treatment is working.
In this study, doctors used a type of PET-CT scan called a fluciclovine PET-CT scan (18F PET-CT scan).
Fluciclovine is a mild
When this study was done, fluciclovine had already been looked at for prostate cancer. Doctors hoped that it would also be useful for breast cancer.
The main aim of this study was to find out how well breast cancer cells take up the fluciclovine dye (tracer).
Summary of results
This study was for women who had been recently diagnosed with breast cancer. They were all due to have treatment. Everyone taking part had a 18F PET-CT scan before they started treatment.
They had an injection of fluciclovine tracer before the scan. The research team measured how much of the tracer was in the breast cancer tissue at various times after the injection.
They looked at the results using two different methods of analysis. One was the standard method. The other was a more involved and complex method.
A total of 39 women joined this study. The results showed that breast cancer tissue took up more of the tracer than the healthy breast tissue around it.
The results of the different mathematical methods were similar. The research team felt that the more involved and complex method didn’t add any more information to the test results.
The research team concluded that fluciclovine could be a useful tracer to use in PET-CT scans for breast cancer.
More detailed information
There is more information about this research in the reference below.
Please note, this article is not in plain English. It has been written for health care professionals and researchers.
Characterising 18F-fluciclovine uptake in breast cancer through the use of dynamic PET/CT imaging
N Scott and others
British Journal of Cancer, 2022. Issue 126, pages 598 - 605.
Where this information comes from
We have based this summary on the information in the article above. This has been reviewed by independent specialists (
How to join a clinical trial
Professor Adrian Harris
Blue Earth Diagnostics Ltd
Cancer Research UK
Engineering and Physical Sciences Research Council (EPSRC)
Medical Research Council (MRC)
Oncology Clinical Trials Office (OCTO)
Oxford Clinical Trials Research Unit (OCTRU)
University of Oxford